These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 26986753)

  • 1. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
    Al-Ani F; Bermejo JM; Mateos MV; Louzada M
    Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
    Larocca A; Cavallo F; Bringhen S; Di Raimondo F; Falanga A; Evangelista A; Cavalli M; Stanevsky A; Corradini P; Pezzatti S; Patriarca F; Cavo M; Peccatori J; Catalano L; Carella AM; Cafro AM; Siniscalchi A; Crippa C; Petrucci MT; Yehuda DB; Beggiato E; Di Toritto TC; Boccadoro M; Nagler A; Palumbo A
    Blood; 2012 Jan; 119(4):933-9; quiz 1093. PubMed ID: 21835953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
    Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
    Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.
    Palumbo A; Rajkumar SV; Dimopoulos MA; Richardson PG; San Miguel J; Barlogie B; Harousseau J; Zonder JA; Cavo M; Zangari M; Attal M; Belch A; Knop S; Joshua D; Sezer O; Ludwig H; Vesole D; Bladé J; Kyle R; Westin J; Weber D; Bringhen S; Niesvizky R; Waage A; von Lilienfeld-Toal M; Lonial S; Morgan GJ; Orlowski RZ; Shimizu K; Anderson KC; Boccadoro M; Durie BG; Sonneveld P; Hussein MA;
    Leukemia; 2008 Feb; 22(2):414-23. PubMed ID: 18094721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.
    Carrier M; Le Gal G; Tay J; Wu C; Lee AY
    J Thromb Haemost; 2011 Apr; 9(4):653-63. PubMed ID: 21255254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.
    Klein U; Kosely F; Hillengass J; Hundemer M; Schmitt S; Neben K; Moehler T; Hegenbart U; Ho AD; Goldschmidt H
    Ann Hematol; 2009 Jan; 88(1):67-71. PubMed ID: 18668241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Multiple myeloma and venous thrombosis. Which thromboprophylaxis should be given?].
    de Moreuil C; Ianotto JC; Eveillard JR; Carrier M; Delluc A
    Rev Med Interne; 2016 Jul; 37(7):473-9. PubMed ID: 26833146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.
    Anaissie EJ; Coleman EA; Goodwin JA; Kennedy RL; Lockhart KD; Stewart CB; Coon SK; Bailey C; Barlogie B
    Cancer; 2012 Jan; 118(2):549-57. PubMed ID: 21720994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.
    Piedra K; Peterson T; Tan C; Orozco J; Hultcrantz M; Hassoun H; Mailankody S; Lesokhin A; Shah U; Lu S; Patel D; Derkach A; Wilkins CR; Korde N
    Br J Haematol; 2022 Jan; 196(1):105-109. PubMed ID: 34396516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
    Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.
    Musallam KM; Dahdaleh FS; Shamseddine AI; Taher AT
    Thromb Res; 2009 Mar; 123(5):679-86. PubMed ID: 18992924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.
    Zamagni E; Brioli A; Tacchetti P; Zannetti B; Pantani L; Cavo M
    Semin Thromb Hemost; 2011 Apr; 37(3):209-19. PubMed ID: 21455855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
    Bagratuni T; Kastritis E; Politou M; Roussou M; Kostouros E; Gavriatopoulou M; Eleutherakis-Papaiakovou E; Kanelias N; Terpos E; Dimopoulos MA
    Am J Hematol; 2013 Sep; 88(9):765-70. PubMed ID: 23757261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silent venous thromboembolism in multiple myeloma patients treated with lenalidomide.
    Isoda A; Sato N; Miyazawa Y; Matsumoto Y; Koumoto M; Ookawa M; Sawamura M; Matsumoto M
    Int J Hematol; 2015 Sep; 102(3):271-7. PubMed ID: 26177588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin use.
    Zoppellaro G; Veronese N; Granziera S; Gobbi L; Stubbs B; Cohen AT
    Semin Hematol; 2018 Oct; 55(4):182-184. PubMed ID: 30502844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.
    Niesvizky R; Martínez-Baños D; Jalbrzikowski J; Christos P; Furst J; De Sancho M; Mark T; Pearse R; Mazumdar M; Zafar F; Pekle K; Leonard J; Jayabalan D; Coleman M
    Leuk Lymphoma; 2007 Dec; 48(12):2330-7. PubMed ID: 18067007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone.
    Shin J; Lee JJ; Kim K; Min CK; Lee JO; Suh C; Kim JS; Lee YJ; Yoon SS; Jo JC; Lee HS; Bang SM;
    Int J Hematol; 2019 Jan; 109(1):79-90. PubMed ID: 30291558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low incidence of thromboembolism in relapsed/refractory myeloma patients treated with thalidomide without thromboprophylaxis in Taiwan.
    Wu SY; Yeh YM; Chen YP; Su WC; Chen TY
    Ann Hematol; 2012 Nov; 91(11):1773-8. PubMed ID: 22706703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematologists' awareness of venous thromboembolism in multiple myeloma: a national survey in China.
    Li Q; Zhang B; Cheng Q; Zhao F; Li J; Yan H; Xu A; Sun C; Hu Y
    Ann Med; 2023; 55(2):2263019. PubMed ID: 37983471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.